PYC Therapeutics Ltd (PYC) - Net Assets
Based on the latest financial reports, PYC Therapeutics Ltd (PYC) has net assets worth AU$170.01 Million AUD (≈ $120.29 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$183.28 Million ≈ $129.68 Million USD) and total liabilities (AU$13.27 Million ≈ $9.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore PYC cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$170.01 Million |
| % of Total Assets | 92.76% |
| Annual Growth Rate | 31.44% |
| 5-Year Change | 215.27% |
| 10-Year Change | 2815.97% |
| Growth Volatility | 252.95 |
PYC Therapeutics Ltd - Net Assets Trend (2004–2025)
This chart illustrates how PYC Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore PYC Therapeutics Ltd (PYC) long-term investment share to see how much of total assets are deployed in long-term investments.
Annual Net Assets for PYC Therapeutics Ltd (2004–2025)
The table below shows the annual net assets of PYC Therapeutics Ltd from 2004 to 2025. For live valuation and market cap data, see PYC Therapeutics Ltd (PYC) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$170.01 Million ≈ $120.29 Million |
+109.75% |
| 2024-06-30 | AU$81.05 Million ≈ $57.35 Million |
+184.98% |
| 2023-06-30 | AU$28.44 Million ≈ $20.12 Million |
-29.25% |
| 2022-06-30 | AU$40.20 Million ≈ $28.45 Million |
-25.45% |
| 2021-06-30 | AU$53.92 Million ≈ $38.15 Million |
+78.58% |
| 2020-06-30 | AU$30.20 Million ≈ $21.37 Million |
+379.34% |
| 2019-06-30 | AU$6.30 Million ≈ $4.46 Million |
+282.41% |
| 2018-06-30 | AU$1.65 Million ≈ $1.17 Million |
-81.41% |
| 2017-06-30 | AU$8.86 Million ≈ $6.27 Million |
+51.95% |
| 2016-06-30 | AU$5.83 Million ≈ $4.13 Million |
+506.03% |
| 2015-06-30 | AU$962.03K ≈ $680.70K |
-74.13% |
| 2014-06-30 | AU$3.72 Million ≈ $2.63 Million |
+211.22% |
| 2013-06-30 | AU$1.19 Million ≈ $845.45K |
-55.64% |
| 2012-06-30 | AU$2.69 Million ≈ $1.91 Million |
-38.11% |
| 2011-06-30 | AU$4.35 Million ≈ $3.08 Million |
+1095.86% |
| 2010-06-30 | AU$-437.08K ≈ $-309.26K |
-122.87% |
| 2009-06-30 | AU$1.91 Million ≈ $1.35 Million |
-29.07% |
| 2008-06-30 | AU$2.69 Million ≈ $1.91 Million |
+22.67% |
| 2007-06-30 | AU$2.20 Million ≈ $1.55 Million |
+3.90% |
| 2006-06-30 | AU$2.11 Million ≈ $1.50 Million |
-63.43% |
| 2005-06-30 | AU$5.78 Million ≈ $4.09 Million |
+958.77% |
| 2004-06-30 | AU$546.00K ≈ $386.33K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PYC Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20619952700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$369.59 Million | 217.95% |
| Other Comprehensive Income | AU$6.18 Million | 3.65% |
| Total Equity | AU$169.57 Million | 100.00% |
PYC Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of PYC Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Civista Bancshares Inc
NASDAQ:CIVB
|
$596.01 Million |
|
Peapack-Gladstone Financial
NASDAQ:PGC
|
$596.09 Million |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
$596.23 Million |
|
Wuhan Langold Real Estate Co Ltd
SHE:002305
|
$596.36 Million |
|
Haier Smart Home Co Ltd
XETRA:690D
|
$595.60 Million |
|
Cass Information Systems Inc
NASDAQ:CASS
|
$595.29 Million |
|
Edom Technology Co Ltd
TW:3048
|
$595.08 Million |
|
Caribbean Utilities Company Ltd
TO:CUP-U
|
$594.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PYC Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 80,495,652 to 169,573,623, a change of 89,077,971 (110.7%).
- Net loss of 50,304,679 reduced equity.
- Share repurchases of 6,802,435 reduced equity.
- New share issuances of 145,815,911 increased equity.
- Other comprehensive income increased equity by 369,174.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-50.30 Million | -29.67% |
| Share Repurchases | AU$6.80 Million | -4.01% |
| Share Issuances | AU$145.82 Million | +85.99% |
| Other Comprehensive Income | AU$369.17K | +0.22% |
| Total Change | AU$- | 110.66% |
Book Value vs Market Value Analysis
This analysis compares PYC Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 682.81x to 4.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-06-30 | AU$0.00 | AU$1.41 | x |
| 2006-06-30 | AU$0.00 | AU$1.41 | x |
| 2007-06-30 | AU$0.00 | AU$1.41 | x |
| 2008-06-30 | AU$0.00 | AU$1.41 | x |
| 2009-06-30 | AU$0.00 | AU$1.41 | x |
| 2010-06-30 | AU$0.00 | AU$1.41 | x |
| 2011-06-30 | AU$0.00 | AU$1.41 | x |
| 2012-06-30 | AU$0.00 | AU$1.41 | x |
| 2013-06-30 | AU$0.00 | AU$1.41 | x |
| 2014-06-30 | AU$0.00 | AU$1.41 | x |
| 2015-06-30 | AU$0.00 | AU$1.41 | x |
| 2016-06-30 | AU$0.00 | AU$1.41 | x |
| 2017-06-30 | AU$0.00 | AU$1.41 | x |
| 2018-06-30 | AU$0.00 | AU$1.41 | x |
| 2019-06-30 | AU$0.00 | AU$1.41 | x |
| 2020-06-30 | AU$0.01 | AU$1.41 | x |
| 2021-06-30 | AU$0.02 | AU$1.41 | x |
| 2022-06-30 | AU$0.01 | AU$1.41 | x |
| 2023-06-30 | AU$0.01 | AU$1.41 | x |
| 2024-06-30 | AU$0.02 | AU$1.41 | x |
| 2025-06-30 | AU$0.34 | AU$1.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PYC Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -214.11%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.08x
- Recent ROE (-29.67%) is above the historical average (-122.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -27.46% | -3020.25% | 0.01x | 1.05x | AU$-2.17 Million |
| 2006 | -188.78% | -816.25% | 0.17x | 1.34x | AU$-4.20 Million |
| 2007 | -177.03% | -1412.09% | 0.08x | 1.61x | AU$-4.11 Million |
| 2008 | -166.40% | -4940.87% | 0.03x | 1.31x | AU$-4.75 Million |
| 2009 | -234.97% | -352.25% | 0.37x | 1.82x | AU$-4.68 Million |
| 2010 | 0.00% | -766.92% | 0.38x | 0.00x | AU$-4.53 Million |
| 2011 | -82.83% | -152.86% | 0.42x | 1.30x | AU$-4.04 Million |
| 2012 | -144.94% | -203.53% | 0.55x | 1.30x | AU$-4.17 Million |
| 2013 | -287.87% | -483.17% | 0.31x | 1.89x | AU$-3.56 Million |
| 2014 | -87.60% | -440.59% | 0.16x | 1.22x | AU$-3.63 Million |
| 2015 | -310.95% | -360.80% | 0.46x | 1.86x | AU$-3.09 Million |
| 2016 | -68.24% | -369765.06% | 0.00x | 1.25x | AU$-4.56 Million |
| 2017 | -22.02% | -70.61% | 0.27x | 1.17x | AU$-2.84 Million |
| 2018 | -451.29% | -15340.48% | 0.01x | 2.08x | AU$-7.60 Million |
| 2019 | -64.76% | -1631906.80% | 0.00x | 1.06x | AU$-4.71 Million |
| 2020 | -23.98% | -284.77% | 0.08x | 1.11x | AU$-9.67 Million |
| 2021 | -33.50% | -577.93% | 0.05x | 1.09x | AU$-23.07 Million |
| 2022 | -35.23% | -86.41% | 0.35x | 1.15x | AU$-17.80 Million |
| 2023 | -82.12% | -144.18% | 0.43x | 1.34x | AU$-25.56 Million |
| 2024 | -46.87% | -171.02% | 0.24x | 1.13x | AU$-45.77 Million |
| 2025 | -29.67% | -214.11% | 0.13x | 1.08x | AU$-67.26 Million |
Industry Comparison
This section compares PYC Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $22,842,466
- Average return on equity (ROE) among peers: -244.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PYC Therapeutics Ltd (PYC) | AU$170.01 Million | -27.46% | 0.08x | $595.86 Million |
| Adalta Ltd (1AD) | $7.75 Million | -36.57% | 0.04x | $7.22 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $5.68 Million | -54.49% | 0.11x | $17.18 Million |
| ACRUX Ltd (ACR) | $9.09 Million | -108.18% | 0.68x | $2.91 Million |
| Actinogen Medical Ltd (ACW) | $17.26 Million | -36.10% | 0.04x | $85.46 Million |
| Argenica Therapeutics Ltd (AGN) | $18.40K | -2084.05% | 19.53x | $10.00 Million |
| Arovella Therapeutics Ltd (ALA) | $13.35 Million | -1.99% | 0.25x | $61.58 Million |
| Anatara Lifesciences Ltd (ANR) | $12.02 Million | -14.18% | 0.02x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $16.55 Million | -72.26% | 0.20x | $69.26 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $49.01 Million |
| Avecho Biotechnology Ltd (AVE) | $135.47 Million | -4.52% | 0.28x | $31.25 Million |
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more